NEUP
MaterialsNeuphoria Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving NEUP Today?
No stock-specific AI insight has been generated for NEUP yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
NEUP News
20 articles- Here's Why We're Not At All Concerned With Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn SituationYahoo Finance·Feb 19, 2026
- Leading Advisory Firms Recommend Voting FOR Lynx1's Independent NomineesYahoo Finance·Dec 8, 2025
- Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director NomineesYahoo Finance·Dec 8, 2025
- Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and PremiumYahoo Finance·Dec 4, 2025
- Lynx1 Sends Open Letter to Fellow Neuphoria ShareholdersYahoo Finance·Dec 2, 2025
- Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 FictionsYahoo Finance·Dec 1, 2025
- Neuphoria Therapeutics Inc. Sends Letter to StockholdersYahoo Finance·Nov 24, 2025
- Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder ValueYahoo Finance·Nov 11, 2025
- Is Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Worth US$4.4 Based On Its Intrinsic Value?Yahoo Finance·Oct 31, 2025
- Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of ProcessYahoo Finance·Oct 27, 2025
- BC-Most Active StocksYahoo Finance·Oct 24, 2025
- Neuphoria scraps social anxiety hopeful after Phase III missClinicaltrialsarena·Oct 22, 2025
- Investors Parse Earnings Reports With US Equity Futures Flat Tuesday Pre-BellYahoo Finance·Oct 21, 2025
- Neuphoria Says Phase 3 Trial of BNC210 to Treat Social Anxiety Disorder Did Not Meet Primary EndpointYahoo Finance·Oct 20, 2025
- Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety DisorderYahoo Finance·Oct 20, 2025
- Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business UpdatesYahoo Finance·Sep 29, 2025
- Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)Yahoo Finance·Sep 4, 2025
- Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Aug 28, 2025
- Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual MeetingYahoo Finance·May 27, 2025
- Neuphoria Provides First Quarter 2025 Business UpdatesYahoo Finance·May 20, 2025
All 20 articles loaded
Price Data
Fundamentals
Trading
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.